Clinical Trials Browser

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoproliferative Disorders, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, T-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Clinical Trials

OPAL

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

MK-1026-003

Soundtrack-E

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

U96-CAR-T-Cells For R/R B-ALL

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

SOUNDTRACK-C1

BRUIN-CLL-314

TITANium

CLL-IMPACT

ACCESS

ACCELERATE

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

OPTIMIZE

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

BaseCAR-01

CASEY

CD22 Redirected Autologous T Cells for ALL

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

CARPASCIO

TRICAR-ALL

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

ARQ 531-101

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

PIPOZA

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia

CLL2-BZAG

CLL-Frail

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

CLL1818

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

ACALLO

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

VTB-CLL002

CLL17

CLL2-BAAG

AMPLIFY